Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

HL-A antigens and multiple sclerosis.
Mitochondrial approaches for neuroprotection.
Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection.
Rescue Therapy Using Rituximab for Multiple Sclerosis.
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.
Risk factors for rare diseases can be risky to define: PML and natalizumab.
Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis.
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3.
Ustekinumab.
Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects.
Altered likelihood of brain activation in attention and working memory networks in patients with multiple sclerosis: An ALE meta-analysis.
Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service.
The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis.
It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.
Increase in mRNA Level of Orexin1 and 2 Receptors Following Induction of Experimental Autoimmune Encephalomyelitis in Mice.
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies.
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease
Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of multiple sclerosis
Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease.
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.

Pages